trending Market Intelligence /marketintelligence/en/news-insights/trending/M43gKA7vFOi4FYOjsxljMw2 content esgSubNav
In This List

Biogen wins MS drug patent dispute against Forward Pharma

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Biogen wins MS drug patent dispute against Forward Pharma

The U.S. Patent Trial and Appeal Board upheld the validity of Biogen Inc.'s patents on its multiple sclerosis drug Tecfidera in a patent interference proceeding against Forward Pharma A/S, Reuters reported March 31.

Forward Pharma's patent description was reportedly found insufficient to declare infringement by Biogen, which will now not owe any future royalty payments to Forward Pharma.

Under the ruling, the exclusivity of Biogen's Tecfidera patents will remain in force until 2028.

Biogen previously paid Forward Pharma $1.25 billion to license the use of Forward Pharma's method to treat multiple sclerosis.